DOCK2-IN-1是一种 DOCK2 抑制剂，IC₅₀ 为 19.1 μM，通过可逆结合 DOCK2 DHR-2 结构域抑制其催化活性，阻断淋巴细胞的活化及趋化反应，适用于免疫和炎症研究。

CPYPP is a DOCK2 inhibitor which bounds to DOCK2 DHR-2 domain in a reversible manner and inhibited its catalytic activity in vitro. It also inhibits DOCK1 and DOCK5 and exhibits selectivity over DOCK9.

TBOPP is a selective DOCK1 inhibitor with IC50 value of 8.4μM. It dampened DOCK1-mediated invasion, macropinocytosis, and survival under the condition of glutamine deprivation. TBOPP treatment suppressed cancer metastasis and growth in vivo in mice.